EcoR1 Capital
Latest statistics and disclosures from EcoR1 Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ZYME, ANAB, JAZZ, CNTA, CRNX, and represent 74.06% of EcoR1 Capital's stock portfolio.
- Added to shares of these 10 stocks: CNTA (+$131M), Aktis Oncology (+$86M), RLAY (+$19M), ERAS (+$15M), Eikon Therapeutics (+$7.8M), REPL (+$7.7M), ZURA (+$7.0M), PHAT (+$6.9M), ETON, STOK.
- Started 10 new stock positions in Eikon Therapeutics, STOK, ERAS, ZURA, Helix Acquisition Corp Iii, PHAT, RLAY, PRLD, REPL, Aktis Oncology.
- Reduced shares in these 10 stocks: IMNM (-$61M), MBX (-$40M), GPCR (-$23M), PCVX (-$21M), AQST (-$17M), VYGR (-$16M), XNCR (-$14M), MNKD (-$9.4M), NUVB.WS (-$8.6M), EOLS.
- Sold out of its positions in AQST, CAMP, EOLS, IMNM, MNKD, NUVB.WS, GPCR, PCVX, VYGR.
- EcoR1 Capital was a net buyer of stock by $77M.
- EcoR1 Capital has $2.4B in assets under management (AUM), dropping by 6.91%.
- Central Index Key (CIK): 0001587114
Tip: Access up to 7 years of quarterly data
Positions held by EcoR1 Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for EcoR1 Capital
EcoR1 Capital holds 29 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Zymeworks Del (ZYME) | 24.4 | $575M | 23M | 25.04 |
|
|
| Anaptysbio Inc Common (ANAB) | 18.5 | $437M | 7.9M | 55.46 |
|
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 13.7 | $323M | 1.7M | 189.05 |
|
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 10.8 | $255M | +105% | 6.4M | 39.72 |
|
| Crinetics Pharmaceuticals In (CRNX) | 6.6 | $156M | 4.3M | 36.32 |
|
|
| Aktis Oncology Com Added | 3.7 | $86M | NEW | 4.8M | 17.89 |
|
| Oric Pharmaceuticals (ORIC) | 3.6 | $85M | 6.7M | 12.67 |
|
|
| Cg Oncology (CGON) | 3.2 | $75M | +3% | 1.1M | 67.68 |
|
| Crispr Therapeutics Namen Akt (CRSP) | 2.8 | $66M | 1.4M | 47.57 |
|
|
| Eton Pharmaceuticals (ETON) | 2.3 | $54M | +6% | 2.2M | 24.68 |
|
| Galapagos Nv Spon Adr (GLPG) | 2.1 | $50M | 1.7M | 30.00 |
|
|
| Xencor (XNCR) | 1.1 | $26M | -34% | 2.2M | 12.06 |
|
| Neurogene (NGNE) | 1.1 | $26M | 1.3M | 20.16 |
|
|
| Bridgebio Oncology Therapeut Com New (BBOT) | 1.1 | $25M | 2.8M | 8.95 |
|
|
| Mbx Biosciences (MBX) | 1.0 | $23M | -63% | 777k | 29.85 |
|
| Relay Therapeutics (RLAY) | 0.8 | $19M | NEW | 1.9M | 9.95 |
|
| Zenas Biopharma (ZBIO) | 0.7 | $15M | 790k | 19.55 |
|
|
| Erasca (ERAS) | 0.6 | $15M | NEW | 900k | 16.18 |
|
| Eikon Therapeutics Com Added | 0.3 | $7.8M | NEW | 733k | 10.58 |
|
| Replimune Group (REPL) | 0.3 | $7.7M | NEW | 1.0M | 7.65 |
|
| Zura Bio Class A Ord Shs (ZURA) | 0.3 | $7.0M | NEW | 1.2M | 5.95 |
|
| Phathom Pharmaceuticals (PHAT) | 0.3 | $6.9M | NEW | 625k | 11.11 |
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.2 | $4.4M | +70% | 13M | 0.33 |
|
| Stoke Therapeutics (STOK) | 0.1 | $3.3M | NEW | 100k | 32.56 |
|
| Prelude Therapeutics (PRLD) | 0.1 | $3.2M | NEW | 947k | 3.42 |
|
| Ibio Com New (IBIO) | 0.1 | $3.0M | -28% | 1.6M | 1.90 |
|
| Helix Acquisition Corp Iii Usd Cl A Ord Shs Added | 0.1 | $2.0M | NEW | 200k | 10.16 |
|
| Atara Biotherapeutics Com New (ATRA) | 0.0 | $471k | -82% | 100k | 4.73 |
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $130k | 4.4k | 29.13 |
|
Past Filings by EcoR1 Capital
SEC 13F filings are viewable for EcoR1 Capital going back to 2014
- EcoR1 Capital 2026 Q1 filed May 15, 2026
- EcoR1 Capital 2025 Q4 filed Feb. 17, 2026
- EcoR1 Capital 2025 Q3 filed Nov. 14, 2025
- EcoR1 Capital 2025 Q2 filed Aug. 14, 2025
- EcoR1 Capital 2025 Q1 filed May 15, 2025
- EcoR1 Capital 2024 Q4 filed Feb. 14, 2025
- EcoR1 Capital 2024 Q3 filed Nov. 14, 2024
- EcoR1 Capital 2024 Q2 filed Aug. 14, 2024
- EcoR1 Capital 2024 Q1 filed May 15, 2024
- EcoR1 Capital 2023 Q4 filed Feb. 14, 2024
- EcoR1 Capital 2023 Q3 filed Nov. 14, 2023
- EcoR1 Capital 2023 Q2 filed Aug. 14, 2023
- EcoR1 Capital 2023 Q1 filed May 15, 2023
- EcoR1 Capital 2022 Q4 filed Feb. 14, 2023
- EcoR1 Capital 2022 Q3 filed Nov. 14, 2022
- EcoR1 Capital 2022 Q2 filed Aug. 15, 2022